# Scribe Therapeutics, Inc. — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_4725a8c87909963fd434 · retrieved 2026-08-11T16:12:47.239Z

## Overview
Scribe Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery and development of biological products.

Eli Lilly and Company acquired 1,054,828 shares of Scribe Therapeutics common stock on July 10, 2026 upon conversion of an 8% Convertible Promissory Note that the company had previously purchased for $30.0 million. Additionally, Eli Lilly purchased 333,333 shares in Scribe's initial public offering at the public offering price of $15.00 per share for approximately $5.0 million. Combined, these transactions give Eli Lilly beneficial ownership of 1,388,161 shares, representing approximately 7.36% of Scribe's outstanding common stock as of July 27, 2026.

## Terms
- Counterparty: Scribe Therapeutics, Inc. · Deal value: $128.7M · Consideration: mixed · Stake: 7.36% · Price/share: $15

## Key dates
- Announced 2026-07-24 · Expected close 2026-07-27

## Timeline
- 2026-07-24 · 424B4 (0001193125-26-316503): 424B4 - Scribe Therapeutics, Inc. — *Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, with initial focus on cardiovascular and metabolic diseases including atherosclerotic cardiovascular disease.* Scribe Therapeutics Inc., a clinical-stage biotechnology company engineering in vivo CRISPR technologies for cardiovascular and metabolic diseases, is conducting an initial public offering of 8,580,000 shares of common stock at $15.00 per share, raising gross proceeds of $128.7 million. The company's common stock has been approved for listing on Nasdaq under the symbol "SCTX." Concurrently, Sanofi has agreed to purchase 500,000 shares at the same $15.00 per share price in a private placement exempt from Securities Act registration, contingent upon and closing concurrently with the IPO. The underwriters have been granted a 30-day option to purchase up to 1,287,000 additional shares at the IPO price less underwriting discounts and commissions. Net proceeds to the company from the IPO and concurrent private placement are estimated at approximately $122.8 million (or $140.7 million if the underwriters exercise their option in full), after deducting underwriting discounts, commissions, and estimated offering expenses.
  https://www.sec.gov/Archives/edgar/data/1853921/0001193125-26-316503.txt
- 2026-07-30 · SCHEDULE 13D (0000059478-26-000072): SCHEDULE 13D - Scribe Therapeutics, Inc. — *Scribe Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery and development of biological products.* Eli Lilly and Company acquired 1,054,828 shares of Scribe Therapeutics common stock on July 10, 2026 upon conversion of an 8% Convertible Promissory Note that the company had previously purchased for $30.0 million. Additionally, Eli Lilly purchased 333,333 shares in Scribe's initial public offering at the public offering price of $15.00 per share for approximately $5.0 million. Combined, these transactions give Eli Lilly beneficial ownership of 1,388,161 shares, representing approximately 7.36% of Scribe's outstanding common stock as of July 27, 2026.
  https://www.sec.gov/Archives/edgar/data/1853921/0000059478-26-000072.txt

## Citations
- 0001193125-26-316503 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526316503
- 0000059478-26-000072 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000005947826000072